Vivek Garipalli - 07 Jan 2026 Form 4 Insider Report for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: CLOV
Reported as of: 07 Jan 2026
Net transaction value: -$4,288,908
SEC form: 4
Accepted by SEC: 09 Jan 2026, 16:08:11 UTC
Prior SEC filing: 08 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/Peter J. Rivas as attorney-in-fact for Vivek Garipalli

Key filing fact

Vivek Garipalli filed Form 4 for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) on 09 Jan 2026.

Key facts

This page summarizes Vivek Garipalli's Form 4 filing for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV).
5 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 09 Jan 2026, 16:08.

Change

Previous filing in this sequence was filed on 08 Aug 2025.
Current net transaction value: -$4,288,908.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001839260 Primary reporting owner

Garipalli Vivek

Relationship: Director, 10%+ Owner
Address: C/O CLOVER HEALTH INVESTMENTS, CORP., NOT APPLICABLE, WILMINGTON
Signature: /s/Peter J. Rivas as attorney-in-fact for Vivek Garipalli
Signature date: 09 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLOV transaction

Class A Common Stock

Options Exercise

Transaction value: $0
Shares: +1,655,949
Change %: +89%
Price: $0.000000
Shares after: 3,512,196
Date: 07 Jan 2026
Ownership: Direct
Footnotes: F1, F2

CLOV transaction

Class A Common Stock

Tax liability

Transaction value: $4,288,908
Shares: -1,655,949
Change %: -47%
Price: $2.59
Shares after: 1,856,247
Date: 07 Jan 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLOV transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
Shares: -3,342,699
Change %: -100%
Price
Shares after: 0
Date: 07 Jan 2026
Ownership: Direct
Underlying class: Class B Common Stock
Underlying amount: 3,342,699
Exercise price
Footnotes: F1, F3

CLOV transaction Derivative

Class B Common Stock

Options Exercise

Transaction value
Shares: +3,342,699
Change %: +48%
Price
Shares after: 10,247,042
Date: 07 Jan 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 3,342,699
Exercise price
Footnotes: F1, F2

CLOV transaction Derivative

Class B Common Stock

Options Exercise

Transaction value
Shares: -1,655,949
Change %: -16%
Price
Shares after: 8,591,093
Date: 07 Jan 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 1,655,949
Exercise price
Footnotes: F1, F2

CLOV holding Derivative

Class B Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 72,084,543
Date: 07 Jan 2026
Ownership: Held by NJ Healthcare Investments, LLC
Underlying class: Class A Common Stock
Underlying amount: 75,694,143
Exercise price
Footnotes: F1, F4

CLOV holding Derivative

Class B Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 11,500,000
Date: 07 Jan 2026
Ownership: Held by Ceasar Clover, LLC
Underlying class: Class A Common Stock
Underlying amount: 11,500,000
Exercise price
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer.

Footnote F2

On January 7, 2026, the final 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,686,750 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,655,949 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event.

Footnote F3

Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vested in equal installments on the first five anniversaries of January 7, 2021.

Footnote F4

The Reporting Person serves as the sole manager of each of NJ Healthcare Investments, LLC and Caesar Clover, LLC.